Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridDemircan, Nazim/0000-0001-6630-5278
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidDemircan, Nazim/HHY-8715-2022
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.contributor.authorKostek, O.
dc.contributor.authorDemircan, N. C.
dc.contributor.authorGokyer, A.
dc.contributor.authorKucukarda, A.
dc.contributor.authorSunal, B. S.
dc.contributor.authorHacioglu, M. B.
dc.contributor.authorEslame, H.
dc.date.accessioned2024-06-12T11:14:10Z
dc.date.available2024-06-12T11:14:10Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurposeWe aimed to assess whether anti-EGFR combined chemotherapy regimens are related with loss of skeletal muscle mass and to compare cetuximab and panitumumab therapies in the aspect of skeletal muscle area change as well as to assess whether skeletal muscle mass loss has prognostic significance in the RAS wild mCRC patients.Materials and methodsA total of 56 patients (30 patients in cetuximab arm and 26 patients in panitumumab) who had computed tomography images were retrospectively evaluated at the diagnosis and follow up during the treatment period before progression.ResultsDuring treatment period 24 patients (42.8%) had muscle loss. Of these, 7 (29.2%) patients were treated at first-line and 17 (70.8%) patients were treated at second-line setting. There was no significant difference in the aspect of skeletal muscle loss among cetuximab and panitumumab combined treatment regimens. Median PFS was 9.1 (8.6-9.6) months in muscle loss group and 13.9 (7.2-20.6) months in muscle stable group (p = 0.001). Median OS was 23.4 (95% CI 15.8-31.0) months in muscle stable group and 19.1 (95% CI 17.0-21.3) months in muscle loss group (p = 0.57) at first-line setting. For second-line, median OS was 21.2 (14.7-27.7) months in muscle stable group and 14.4 (6.0-22.4) months in muscle loss group (p = 0.003).ConclusionsDecrease in skeletal muscle mass before progression on CT imaging is an independent indicator for shorter PFS value in RAS WT mCRC patients who received anti-EGFR combined chemotherapy regimens at both the first and second-line settings. Beside that shorter overall survival values also were significantly seen in patients who had muscle loss during anti-EGFR therapy in the second-line setting.en_US
dc.identifier.doi10.1007/s12094-019-02079-x
dc.identifier.endpage1517en_US
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.issue11en_US
dc.identifier.pmid30924091en_US
dc.identifier.scopus2-s2.0-85073595404en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1510en_US
dc.identifier.urihttps://doi.org/10.1007/s12094-019-02079-x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23833
dc.identifier.volume21en_US
dc.identifier.wosWOS:000493999400008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer International Publishing Agen_US
dc.relation.ispartofClinical & Translational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSkeletal Muscle Massen_US
dc.subjectAnti-EGFR Treatmenten_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectPrognosisen_US
dc.subjectRandomized Phase-Iiien_US
dc.subject1st-Line Treatmenten_US
dc.subjectOpen-Labelen_US
dc.subjectPanitumumaben_US
dc.subjectCetuximaben_US
dc.subjectFluorouracilen_US
dc.subjectLeucovorinen_US
dc.subjectSarcopeniaen_US
dc.subjectMassen_US
dc.subjectBevacizumaben_US
dc.titleSkeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu